415 related articles for article (PubMed ID: 31411090)
1. Association Between Baseline, Achieved, and Reduction of CRP and Cardiovascular Outcomes After LDL Cholesterol Lowering with Statins or Ezetimibe: A Systematic Review and Meta-Analysis.
Zhang XL; Lan RF; Zhang XW; Xu W; Wang L; Kang LN; Xu B
J Am Heart Assoc; 2019 Aug; 8(16):e012428. PubMed ID: 31411090
[TBL] [Abstract][Full Text] [Related]
2. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.
Navarese EP; Robinson JG; Kowalewski M; Kolodziejczak M; Andreotti F; Bliden K; Tantry U; Kubica J; Raggi P; Gurbel PA
JAMA; 2018 Apr; 319(15):1566-1579. PubMed ID: 29677301
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of the Relation of Body Mass Index to Cardiovascular Outcomes in Patients Receiving Intensive Low-Density Lipoprotein Cholesterol Lowering Therapy.
Khan SU; Khan MU; Riaz H; Raggi P; Valavoor S; Khan MZ; Kołodziejczak M; Khan MS; Krupica T; Alkhouli M; Navarese EP
Am J Cardiol; 2020 Mar; 125(5):727-734. PubMed ID: 31898964
[TBL] [Abstract][Full Text] [Related]
4. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials.
Koskinas KC; Siontis GCM; Piccolo R; Mavridis D; Räber L; Mach F; Windecker S
Eur Heart J; 2018 Apr; 39(14):1172-1180. PubMed ID: 29069377
[TBL] [Abstract][Full Text] [Related]
5. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Bohula EA; Giugliano RP; Cannon CP; Zhou J; Murphy SA; White JA; Tershakovec AM; Blazing MA; Braunwald E
Circulation; 2015 Sep; 132(13):1224-33. PubMed ID: 26330412
[TBL] [Abstract][Full Text] [Related]
6. Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials.
Yang W; Cai X; Lin C; Lv F; Zhu X; Han X; Ji L
Medicine (Baltimore); 2022 Sep; 101(37):e30563. PubMed ID: 36123891
[TBL] [Abstract][Full Text] [Related]
7. Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials.
Lee M; Cheng CY; Wu YL; Lee JD; Hsu CY; Ovbiagele B
JAMA Neurol; 2022 Apr; 79(4):349-358. PubMed ID: 35188949
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia.
Avellone G; Di Garbo V; Guarnotta V; Scaglione R; Parrinello G; Purpura L; Torres D; Campisi D
Int Angiol; 2010 Dec; 29(6):514-24. PubMed ID: 21173733
[TBL] [Abstract][Full Text] [Related]
9. Effect of Low-Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta-Analyses, and Meta-Regression Analyses of Randomized Trials.
Thomopoulos C; Skalis G; Michalopoulou H; Tsioufis C; Makris T
Clin Cardiol; 2015 Dec; 38(12):763-9. PubMed ID: 26282344
[TBL] [Abstract][Full Text] [Related]
10. Effect of More Intensive LDL-C-Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis.
Jin S; Nie X; Li Y; Yuan J; Cui Y; Zhao L
Clin Ther; 2021 Jul; 43(7):e217-e229. PubMed ID: 34092409
[TBL] [Abstract][Full Text] [Related]
11. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
[TBL] [Abstract][Full Text] [Related]
12. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
13. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
14. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.
Silverman MG; Ference BA; Im K; Wiviott SD; Giugliano RP; Grundy SM; Braunwald E; Sabatine MS
JAMA; 2016 Sep; 316(12):1289-97. PubMed ID: 27673306
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
Gencer B; Marston NA; Im K; Cannon CP; Sever P; Keech A; Braunwald E; Giugliano RP; Sabatine MS
Lancet; 2020 Nov; 396(10263):1637-1643. PubMed ID: 33186535
[TBL] [Abstract][Full Text] [Related]
16. Under-representation of ethnic and regional minorities in lipid-lowering randomized clinical trials: a systematic review and meta-analysis.
Sawant S; Wang N
Eur J Prev Cardiol; 2023 Aug; 30(11):1120-1131. PubMed ID: 36748994
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety for the achievement of guideline-recommended lower low-density lipoprotein cholesterol levels: a systematic review and meta-analysis.
Khan SU; Khan MU; Virani SS; Khan MS; Khan MZ; Rashid M; Kalra A; Alkhouli M; Blaha MJ; Blumenthal RS; Michos ED
Eur J Prev Cardiol; 2022 Feb; 28(18):2001-2009. PubMed ID: 33624058
[TBL] [Abstract][Full Text] [Related]
18. Role of non-statin lipid-lowering therapy in coronary atherosclerosis regression: a meta-analysis and meta-regression.
Masson W; Lobo M; Siniawski D; Molinero G; Masson G; Huerín M; Nogueira JP
Lipids Health Dis; 2020 May; 19(1):111. PubMed ID: 32460779
[TBL] [Abstract][Full Text] [Related]
19. Extent of Low-density Lipoprotein Cholesterol Reduction and All-cause and Cardiovascular Mortality Benefit: A Systematic Review and Meta-analysis.
Ennezat PV; Guerbaai RA; Maréchaux S; Le Jemtel TH; François P
J Cardiovasc Pharmacol; 2023 Jan; 81(1):35-44. PubMed ID: 36027598
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
